The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Barclays Lifts FTSE's Lenders

Fri, 23rd Oct 2020 10:46

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.

----------

FTSE 100 - WINNERS

----------

Barclays up 6.2%. The lender kicked off the UK banking reporting season with a "resilient" performance in the third quarter of 2020. Barclays said pretax profit for the three months ended September came in at GBP1.15 billion, up sharply from GBP246 million a year earlier. Third-quarter group income declined 6% to GBP5.20 billion from GBP5.54 billion, however. Other FTSE 100 lenders rose in a positive read-across. StanChart climbed 4.7%, Lloyds was up 4.4%, HSBC rose 3.8% and NatWest was up 3.3%. They all report third-quarter results next week.

----------

FTSE 250 - LOSERS

----------

Airtel Africa down 4.5%. The Africa-focused mobile operator halved its interim dividend to 1.5 US cents from 3 cents a year earlier. Revenue in the first half of 2020 increased by 11% to USD1.82 billion from USD1.65 billion a year ago, with second-quarter revenue growth of 14%. Reported operating profit for the half year was USD472 million, up 20% year-on-year.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Pendragon, up 21%. The motor retailer is piling on more gains after surging 23% on Thursday. It had said Thursday that underlying pretax profit for the three months to ended September was GBP27.3 million, up sharply from GBP3.0 million from a year earlier.

----------

Goco Group up 6.3%. The price comparison site said revenue in the nine months ended September is up 13% annually at GBP130.5 million. Customers at its AutoSave Live arm have more than doubled to 597 from 241 a year earlier.

----------

Evgen Pharma, up 16%. The clinical stage drug development firm has landed all regulatory approvals for the STAR trial of its SFX-01 treatment. The drug is used to treat acute respiratory infections. Recruitment for the trial will begin at the end of October.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Avingtrans PLC, down 7.4%. Shareholder Nigel Wray sold 3.2 million shares in the company at 250 pence each, landing GBP8.1 million. Wray no longer has a stake in the company, which provides systems and services to the energy and industrial sectors.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
22 Mar 2021 14:32

IN BRIEF: Evgen Pharma names Helen Kuhlman as chief business officer

IN BRIEF: Evgen Pharma names Helen Kuhlman as chief business officer

Read more
22 Mar 2021 09:08

Evgen appoints Helen Kuhlman as chief business officer

(Sharecast News) - Clinical-stage drug development company Evgen announced on Monday that Helen Kuhlman had been appointed to the post of chief business officer, taking up the role from 1 April.

Read more
11 Mar 2021 20:08

IN BRIEF: Evgen says no patient safety concerns in STAR Covid-19 trial

IN BRIEF: Evgen says no patient safety concerns in STAR Covid-19 trial

Read more
11 Mar 2021 15:12

Evgen Covid-19 trial given all-clear on safety and data

(Sharecast News) - Clinical stage drug development company Evgen Pharma announced on Thursday that after a review of the first 60 patients enrolled, the data safety monitoring committee for the 'STAR' Covid-19 trial had concluded that there were no concerns over patient safety or data quality that would prevent its continuation.

Read more
3 Mar 2021 20:16

TRADING UPDATES: Cambria drives on amid virus; Argo crypto mining up

TRADING UPDATES: Cambria drives on amid virus; Argo crypto mining up

Read more
24 Feb 2021 16:09

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
17 Feb 2021 15:10

Evgen makes progress with recruitment in 'STAR' trial

(Sharecast News) - Clinical stage drug development company Evgen Pharma said on Wednesday that a total of 102 patients had been recruited and randomised to the 'STAR', or 'SFX-01 Treatment for Acute Respiratory infections', trial.

Read more
17 Feb 2021 11:15

IN BRIEF: Evgen Pharma Recruits Over 100 For Respiratory Drug Trial

IN BRIEF: Evgen Pharma Recruits Over 100 For Respiratory Drug Trial

Read more
3 Feb 2021 11:49

IN BRIEF: Intuitive Investments Buys Shares in Evgen For GBP175,000

IN BRIEF: Intuitive Investments Buys Shares in Evgen For GBP175,000

Read more
2 Feb 2021 17:45

IN BRIEF: Evgen Pharma's GBP11 Fundraise To Support Lead Candidate

IN BRIEF: Evgen Pharma's GBP11 Fundraise To Support Lead Candidate

Read more
22 Jan 2021 08:53

Evgen Shares Rise On Further Positive Test Results For SFX-01

Evgen Shares Rise On Further Positive Test Results For SFX-01

Read more
21 Jan 2021 13:20

IN BRIEF: Evgen Pharma Notes Positive Preclinical Data For SFX-01

IN BRIEF: Evgen Pharma Notes Positive Preclinical Data For SFX-01

Read more
19 Jan 2021 17:34

IN BRIEF: Evgen Pharma Recruits Patients For STAR-Covid-19 Trial

IN BRIEF: Evgen Pharma Recruits Patients For STAR-Covid-19 Trial

Read more
10 Dec 2020 17:07

UK EARNINGS SUMMARY: Character Group Lowers Dividend As Profit Drops

UK EARNINGS SUMMARY: Character Group Lowers Dividend As Profit Drops

Read more
10 Dec 2020 15:45

Evgen Pharma performs in line with forecasts in first half

(Sharecast News) - Clinical-stage drug development company Evgen Pharma reported financial performance in line with its expectations in its first half on Thursday, with revenue coming in at £0.19m, compared to nil a year earlier.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.